NOW ENROLLING

Patients with Transthyretin (TTR)-Mediated Amyloidosis with Familial Amyloidotic Polyneuropathy (FAP)

PROFESSIONAL SUPPORT · COMPREHENSIVE MONITORING · PERSONAL ATTENTION

APOLLO
Sponsored by Alnylam Pharmaceuticals, Inc.

APOLLO: A PHASE 3 CLINICAL TRIAL

APOLLO is a global clinical trial evaluating an investigational drug for TTR amyloidosis with familial amyloidotic polyneuropathy (FAP).

HOW PATISIRAN MAY WORK

Patisiran uses the body's natural processes to lower the levels of TTR protein that cause TTR amyloidosis (FAP). It does so by targeting and silencing specific messenger RNA, blocking the production of TTR protein before it's made. This may help significantly reduce the level of TTR protein in the body, which may slow or halt the progression of TTR amyloidosis (FAP).

Patisiran has already been studied in Phase 2 clinical trials.

The APOLLO trial is now evaluating this investigational drug in a wide range of participants with TTR amyloidosis (FAP).

Could you be ELIGIBLE?*

- ☐ 18 to 85 years old
- ☐ Diagnosed with FAP, with a documented TTR mutation
- ☐ Have adequate cardiac function
- ☐ No prior liver transplant (and no plans to undergo one)
- ☐ No current tetramer stabilizer use (wash out period of 14 days for tafamidis, 3 days for diflunisal)

*This is a list of key APOLLO eligibility criteria. For more information, search **NCT01960348** on **ClinicalTrials.gov** or contact Alnylam's clinical trial hotline at **+1.866.330.0326**.

APOLLO is actively enrolling patients with TTR amyloidosis (FAP)

To learn more contact Alnylam's clinical trial hotline at **+1.866.330.0326 or clinicaltrials@alnylam.com**

APOLLO
Sponsored by Alnylam Pharmaceuticals, Inc.

APOLLO Study Design

APOLLO is a Phase 3, randomized, double-blind, placebo-controlled multinational study. Approximately 200 patients will be enrolled in the study.



What To Expect

All APOLLO participants will be randomly assigned to receive either patisiran or placebo. Two out of 3 participants will receive patisiran.

For up to 18 months, participants will receive their assigned study drug (patisiran or placebo) once every 3 weeks along with study-related monitoring and care.

At 9 and 18 months, participants will also have extensive, all-day exams* to see how the study drug may be affecting their TTR amyloidosis (FAP). Participants whose condition has progressed significantly by 9 months will work with their study doctor to determine next steps.

Participants who complete their 18-month assessment may be eligible to receive patisiran as part of an extended clinical trial.†

** Participants may need to travel to some or all of these visits. We understand that this may require some effort for participants and caregivers, and we'll do our best to make travel as convenient and comfortable as possible. Call 1.866.330.0326 to learn more about the travel-related services study centers can offer.*

† The extended clinical trial is expected to commence in 2015. Participants must meet certain eligibility criteria in order to take part.

IF YOU HAVE TTR AMYLOIDOSIS (FAP) SPEAK WITH YOUR DOCTOR TO LEARN MORE ABOUT APOLLO

Contact Alnylam Pharmaceuticals clinical trial hotline at **+1.866.330.0326** or email **clinicaltrials@alnylam.com**

This clinical trial for patients with TTR amyloidosis (FAP) is sponsored by Alnylam Pharmaceuticals, Inc. Alnylam is a biopharmaceutical company leading the study of a new class of investigational medicines for conditions like TTR amyloidosis (FAP). These investigational medicines have genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

300 Third Street | Cambridge, MA 02142 USA

Alnylam® PHARMACEUTICALS